Roche wins FDA Priority Review for Enspryng in MOGAD
Roche has secured FDA Priority Review for a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmune condition of the central nervous system for which no approved treatments currently exist. The PDUFA date is set for 10 January 2027.
The filing is supported by data from the Phase III METEOROID study, presented at the American Academy of Neurology Annual Meeting in April 2026. The trial met its primary endpoint of time to first relapse during the double-blind treatment period. Enspryng reduced the risk of relapse by 68% versus placebo (p=0.0025), with 87% of patients on the active arm remaining relapse-free at 48 weeks compared with 67% on placebo. Significant improvements were also recorded across secondary endpoints, including annualised relapse rate, MRI lesion activity and rescue therapy use.
Regulatory path
Alongside the US review, the European Medicines Agency has validated a Marketing Authorisation Application for Enspryng in MOGAD, with a European Commission decision anticipated in the third quarter of 2027. This is the second FDA Priority Review granted to Enspryng within a matter of months, following acceptance of the sBLA for thyroid eye disease in June 2026, for which an approval decision is expected in October 2026.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the drug had "the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants."
Enspryng is a humanised monoclonal antibody developed by Chugai, the Roche Group subsidiary, that targets the interleukin-6 (IL-6) receptor using a recycling antibody technology designed to provide sustained pathway suppression. The drug already carries approval in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), giving it a well-characterised safety profile across more than 10,000 patients. The METEOROID safety data were consistent with that established record.
Market context
MOGAD is estimated to affect between 0.51 and 3.42 people per 100,000, placing it firmly in the rare-disease category. Its clinical overlap with NMOSD has historically made it difficult to diagnose and treat distinctly, and the absence of any approved disease-modifying therapy means patients currently rely on off-label immunosuppressants and high-dose corticosteroids during acute attacks.
The rare neuroimmunology space has drawn increased commercial interest in recent years, partly driven by the success of anti-CD20 biologics and complement inhibitors in adjacent indications such as NMOSD and generalised myasthenia gravis. If approved, Enspryng would face competitive pressure from investigational agents across different mechanistic classes that are also being evaluated in MOGAD, though Roche's first-mover advantage with an established manufacturing and commercial infrastructure for satralizumab is a meaningful structural asset. Roche is also developing Enspryng for autoimmune encephalitis, signalling a broader IL-6 inhibition strategy across rare CNS autoimmune indications.
Investors will be watching the October 2026 TED approval decision closely, as a positive outcome there would provide additional regulatory confidence ahead of the January 2027 MOGAD deadline.